ArticleOncotarget2015
Comprehensive characterization of chemotherapeutic efficacy on metastases in the established gastric neuroendocrine cancer patient derived xenograft model.
Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 40 citations in OpenAlex.
- Circulating tumour cell-derived xenograft as a preclinical platform for metastatic breast cancer.British journal of cancer · 2026Article
- Article
- Preclinical Models of Neuroendocrine Neoplasia.Cancers · 2022Review
- Role of aneuploid circulating tumor cells and CD31Molecular oncology · 2021Article
- Identification and Comprehensive Co-Detection of Necrotic and Viable Aneuploid Cancer Cells in Peripheral Blood.Cancers · 2021Article
- Review
- Review
- Strategies for enrichment of circulating tumor cells.Translational cancer research · 2020Review
- Overexpression of Smac by an Armed Vesicular Stomatitis Virus Overcomes Tumor Resistance.Molecular therapy oncolytics · 2019Article
- Systems Biology of Cancer Metastasis.Cell systems · 2019Review
- Karyotyping of circulating tumor cells for predicting chemotherapeutic sensitivity and efficacy in patients with esophageal cancer.BMC cancer · 2019Article
- Aneuploid CTC and CEC.Diagnostics (Basel, Switzerland) · 2018Review
- Application of a novel liquid biopsy in patients with hepatocellular carcinoma undergoing liver transplantation.Oncology letters · 2018Article
- Gastroenteropancreatic neuroendocrine neoplasms: genes, therapies and models.Disease models & mechanisms · 2018Review
- Cell Migration Related to MDR-Another Impediment to Effective Chemotherapy?Molecules (Basel, Switzerland) · 2018Review
- Octreotide Does Not Inhibit Proliferation in Five Neuroendocrine Tumor Cell Lines.Frontiers in endocrinology · 2018Article
- Comprehensive in situ co-detection of aneuploid circulating endothelial and tumor cells.Scientific reports · 2017Article
- Detection of Circulating Tumor Cells Using Negative Enrichment Immunofluorescence and an In Situ Hybridization System in Pancreatic Cancer.International journal of molecular sciences · 2017Article
- Circulating and disseminated tumor cells: diagnostic tools and therapeutic targets in motion.Oncotarget · 2017Review
- Aneuploidy of chromosome 8 in circulating tumor cells correlates with prognosis in patients with advanced gastric cancer.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The HuPrime® human gastric neuroendocrine carcinoma derived xenograft model GA0087 was established in this study. GA0087 PDX model showed high gene expression of vascular endothelial growth factors (VEGF)-A and B, and high potential of lung metastasis. Circulating tumor cells (CTCs) with either large or small size, circulating tumor microemboli (CTM) and lung metastatic lesions were detected in GA0087 PDX mice. The number of CTC correlated to the number of metastatic nodules in lung. Both primary tumor growth and metastasis in terms of the number of dynamically monitored CTCs and metastatic nodules were effectively suppressed by Cisplatin. Diverse subtypes of CTCs in the context of sensitivity to Cisplatin were specifically identified by subtraction enrichment (SE) integrated with in situ Phenotyping of cytokeratin 18 (CK18) and Karyotyping of chromosome 8 (in situ PK CTC by CK-iFISH). All the CK18-/diploid and majority of CK18+/diploid CTC subtypes were chemosensitive, whereas a higher percentage of CK18+/multiploid subtype of CTC were Cisplatin-insensitive. Combined histopathological examination of metastatic lesion and in situ PK CTC in a metastatic PDX (mPDX) tumor model are of particular significance, and may provide an unique and robust platform for cancer research as well as pre-clinical evaluation of therapeutic efficacy of new anti-cancer drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.